Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates
Thu, May 28
|Webinar
Live with Dr. Terry Kenakin (UNC Chapel Hill | Terry's Corner). The biological basis of receptor signaling bias, how to detect and quantify it, and how these data guide lead selection in GPCR drug discovery. In collaboration with Eurofins DiscoverX.
Time & Location
May 28, 2026, 11:00 AM – 12:00 PM
Webinar
About the event
Presented in collaboration with Eurofins DiscoverX
Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates
A live webinar on signaling bias as a quantifiable, decision-useful property in GPCR drug discovery. Dr. Terry Kenakin walks through the biology, the assays that make bias measurable rather than anecdotal, and how to translate pathway-level data into candidate selection and optimization decisions.
Speaker
Dr. Terry Kenakin, Professor of Pharmacology and Pharmacology Course Coordinator, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill. One of the foundational voices on receptor theory and biased signaling, Terry co-developed the quantitative framework the field uses today to describe functional selectivity. He is the author of A Pharmacology Primer, Editor-in-Chief of the Journal of Receptors and Signal Transduction, and a Fellow of the British Pharmacological Society.
Topics Covered
Tickets
General Admission
A live session with Dr. Terry Kenakin (UNC Chapel Hill) on receptor signaling bias as a property of new drug candidates. The biology, the assays that make bias quantifiable, and how these data inform lead selection and optimization in GPCR drug discovery. In collaboration with Eurofins DiscoverX.
$0.00
Sale ended